PATENT CLAIM ANALYSIS

Application Number: 15866669
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["540", "465000"]

Abstract:
The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies.

Claim (Index 13):
A theranostic system according to any one of  claims 1  to  11 , wherein the system comprises a complex of Formula III or Formula IV wherein R 1e , R 1f , R 2 , R 3  and the beacon are as defined in any one of  claims 2  to  8  and  10  and  11 , and L is a linker selected from the group consisting of (i) a poly(ethylene glycol) linker, (ii) a C 1 -C 20  aliphatic chain; and (iii) a conjugate of a poly(ethylene glycol) linker with a C 1 -C 20  aliphatic chain, wherein the poly(ethylene glycol) linker and the C 1 -C 20  aliphatic chain are conjugated via a peptidic or esteric bond.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 1.39394
- Patent Class: 540.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14751795', '10704120', '12209738', '11852604', '11807201']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6935215703171571
- 35 USC 102 Novelty (BERT): 0.594081454577086
- Combined Prediction Score: 0.68357755874315
- Mean Citation Score: 314.902338
- Max Citation Score: 570.9696
- Similarity Product: 388.0745699661255

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test